Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.56 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.56 |
| ▸ | ABL2 | P42684 | 1/20 | 0.56 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BMP4 | P12644 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547877 | 1.00 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL29504909 | 1.00 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373433 | 0.89 | TGFBR1 (0.56) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373271 | 0.84 | TGFBR1 (0.59) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373583 | 0.84 | MAPK14 (0.55) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL372779 | 0.83 | MAPK14 (0.61) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL376179 | 0.83 | TGFBR1 (0.67) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL373351 | 0.83 | TGFBR1 (0.61) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| SCHEMBL18292297 | 0.81 | NFATC1 (0.51) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 | |
| Fluoromethane SCHEMBL27755992 | 0.81 | TGFBR1 (0.64) | TGFBR1MAPK14TGFBR2ABL2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 640 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| US-20250382575-A1 | PROCESS FOR OBTAINING FUNCTIONAL LYMPHOCYTES CELLS | NANTES UNIVERSITÉ (FR) | 2025-12-18 | — | — | US | claimed |
| EP-3047017-B1 | METHODS OF MAMMALIAN RETINAL STEM CELL PRODUCTION AND APPLICATIONS | UNIV CALIFORNIA (US) | 2025-09-10 | — | — | EP | claimed |
| US-12371664-B2 | Medium for direct differentiation of pluripotent stem cell-derived mesenchymal stem cell, method for preparing mesenchymal stem cell by using same, and mesenchymal stem cell prepared thereby | CHA BIOTECH CO., LTD. (KR) | 2025-07-29 | — | — | US | claimed |
| WO-2025090770-A1 | GENERATION OF PARATHYROID-LIKE CELLS | YALE UNIVERSITY (US) | 2025-05-01 | — | — | WO | claimed |
| EP-4540371-A1 | PROCESS FOR OBTAINING FUNCTIONAL LYMPHOCYTES CELLS | Nantes Université (FR) | 2025-04-23 | — | — | EP | claimed |
| WO-2024210619-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | 재단법인 아산사회복지재단 | 2024-10-10 | — | — | WO | claimed |
| US-12065671-B2 | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-20 | — | — | US | claimed |
| US-20240271089-A1 | METHODS TO GENERATE MACULAR, CENTRAL AND PERIPHERAL RETINAL PIGMENT EPITHELIAL CELLS | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-08-15 | — | — | US | claimed |
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | claimed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | claimed |
| WO-2012034101-A2 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | WO | claimed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | claimed |
| CN-101878298-A | Differentiation of human embryonic stem cells | LIFESCAN INC | 2010-11-03 | — | — | CN | claimed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | claimed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | claimed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | claimed |
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2006-02-02 | — | — | US | claimed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
| US-20060025451-A1 | Novel pyrazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885MAPK14 189/4885TGFBR2 3/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885TGFBR2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.